Literature DB >> 28791571

Peripheral Lymphocyte Subsets as a Marker of Parkinson's Disease in a Chinese Population.

Luan Cen1,2, Chaohao Yang3, Shuxuan Huang3, Miaomiao Zhou3, Xiaolu Tang3, Kaiping Li4, Wenyuan Guo3, Zhuohua Wu3, Mingshu Mo3, Yousheng Xiao1,2, Xiang Chen2, Xinling Yang5, Qinhui Huang3,4, Chaojun Chen6, Shaogang Qu7, Pingyi Xu8,9.   

Abstract

In this study, we conducted a clinical analysis of lymphocyte subtypes in 268 patients with Parkinson's disease (PD) to assess their clinical impact as a potential marker of advanced PD in Chinese patients. The participants comprised 268 sporadic PD patients and 268 healthy controls. The numbers of natural killer (NK) cells and CD3+, CD3+CD4+, CD3+CD8+, and CD19+ lymphocytes from peripheral blood were determined by immunostaining and flow cytometric analysis and the percentages of these CD+ T cells were calculated. The ratio of regulatory T (Treg)/helper T 17 (Th17) lymphocytes from 64 PD patients and 46 controls was determined by flow cytometric analysis. The results showed that the percentage of NK cells was higher in advanced PD patients than in controls (22.92% ± 10.08% versus 19.76% ± 10.09%, P = 0.006), while CD3+ T cells are decreased (62.93% ± 9.27% versus 65.75% ± 9.13%, P = 0.005). The percentage of CD19+ B cells in male patients was lower (P = 0.021) than in female patients, whereas NK cells were increased (P < 0.0001). The scores on the Unified Parkinson's Disease Rating Scale (UPDRS) and the Non-Motor Symptoms Scale in late-onset PD patients were significantly higher than those in early-onset patients (P = 0.024 and P = 0.007, respectively). The percentage of CD19+ B cells in patients with UPDRS scores >24 was lower than in those with scores <24 (10.17% ± 4.19% versus 12.22% ± 5.39%, P = 0.009). In addition, the Treg/Th17 ratio in female patients was higher than that in female controls (13.88 ± 6.32 versus 9.94 ± 4.06, P = 0.042). These results suggest that the percentages of NK cells, CD3+ T cells, and CD19+ B cells along with the Treg/Th17 ratio in peripheral blood may be used to predict the risk of PD in Chinese individuals and provide fresh avenues for novel diagnostic biomarkers and therapeutic designs.

Entities:  

Keywords:  Biological marker; Lymphatic cell; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28791571      PMCID: PMC5636734          DOI: 10.1007/s12264-017-0163-9

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  36 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

2.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

Authors:  Ashley D Reynolds; Rebecca Banerjee; Jianou Liu; Howard E Gendelman; R Lee Mosley
Journal:  J Leukoc Biol       Date:  2007-08-03       Impact factor: 4.962

Review 3.  Age-associated changes within CD4+ T cells.

Authors:  Rania D Kovaiou; Beatrix Grubeck-Loebenstein
Journal:  Immunol Lett       Date:  2006-08-14       Impact factor: 3.685

4.  CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence.

Authors:  Piotr Trzonkowski; Ewa Szmit; Jolanta Myśliwska; Andrzej Myśliwski
Journal:  Clin Immunol       Date:  2006-03-20       Impact factor: 3.969

Review 5.  Estrogen receptors in immunity and autoimmunity.

Authors:  Melissa Cunningham; Gary Gilkeson
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 6.  Pharmacological treatment of Parkinson disease: a review.

Authors:  Barbara S Connolly; Anthony E Lang
Journal:  JAMA       Date:  2014 Apr 23-30       Impact factor: 56.272

7.  Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.

Authors:  M Baldereschi; A Di Carlo; W A Rocca; P Vanni; S Maggi; E Perissinotto; F Grigoletto; L Amaducci; D Inzitari
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

8.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Authors:  E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner
Journal:  Neurology       Date:  2006-11-02       Impact factor: 9.910

Review 9.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

10.  Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.

Authors:  Carmen Noelker; Lydie Morel; Anke Osterloh; Daniel Alvarez-Fischer; Thomas Lescot; Minka Breloer; Maike Gold; Wolfgang H Oertel; Carmen Henze; Patrick P Michel; Richard C Dodel; Lixia Lu; Etienne C Hirsch; Stéphane Hunot; Andreas Hartmann
Journal:  J Neuroinflammation       Date:  2014-05-08       Impact factor: 8.322

View more
  19 in total

1.  Content of Peripheral Blood T- and B-Cell Subpopulations in Transgenic A53T Mice of Different Age (A Model of Parkinson's Disease).

Authors:  G V Idova; E L Al'perina; M M Gevorgyan; M A Tikhonova; S Ya Zhanaeva
Journal:  Bull Exp Biol Med       Date:  2021-03-16       Impact factor: 0.804

2.  Biomarker Discovery in Parkinson's Disease: Present Challenges and Future Opportunities.

Authors:  Song Li; Weidong Le
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

Review 3.  Interaction Between Innate Lymphoid Cells and the Nervous System.

Authors:  Yuanyue Zhang; Rachel Grazda; Qi Yang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  New Insights and Implications of Natural Killer Cells in Parkinson's Disease.

Authors:  Kelly B Menees; Jae-Kyung Lee
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

5.  Pathological Role of Natural Killer Cells in Parkinson's Disease: A Systematic Review.

Authors:  Le Zhang; Yingshuang Zhang; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

Review 6.  T Lymphocytes in Parkinson's Disease.

Authors:  Elena Contaldi; Luca Magistrelli; Cristoforo Comi
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

7.  NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.

Authors:  Rachael H Earls; Kelly B Menees; Jaegwon Chung; Claire-Anne Gutekunst; Hyun Joon Lee; Manuel G Hazim; Balázs Rada; Levi B Wood; Jae-Kyung Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-03       Impact factor: 11.205

8.  Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease.

Authors:  Congcong Sun; Zhenxiang Zhao; Wenfei Yu; Mingshu Mo; Chengyuan Song; Youfeng Si; Yiming Liu
Journal:  Ann Transl Med       Date:  2019-11

9.  Evidence for Peripheral Immune Activation in Parkinson's Disease.

Authors:  Xueping Chen; Weihua Feng; Ruwei Ou; Jiao Liu; Jing Yang; Jiajia Fu; Bei Cao; Yongping Chen; Qianqian Wei; Huifang Shang
Journal:  Front Aging Neurosci       Date:  2021-04-30       Impact factor: 5.750

10.  Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.

Authors:  Ruwani S Wijeyekoon; Deborah Kronenberg-Versteeg; Kirsten M Scott; Shaista Hayat; Wei-Li Kuan; Jonathan R Evans; David P Breen; Gemma Cummins; Joanne L Jones; Menna R Clatworthy; R Andres Floto; Roger A Barker; Caroline H Williams-Gray
Journal:  Brain Behav Immun       Date:  2020-01-30       Impact factor: 19.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.